Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NVD 001

Next Previous
Drug Profile

NVD 001

Alternative Names: Creost®; NVD-001

Latest Information Update: 28 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novadip Biosciences
  • Class Pluripotent stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Spondylolisthesis
  • No development reported Pseudoarthrosis

Most Recent Events

  • 28 Feb 2023 No recent reports of development identified for clinical-Phase-Unknown development in Pseudoarthrosis in Belgium (Implant, Implant)
  • 15 Jun 2021 Final efficacy data from the Spine1 phase I/II trial in Spondylolisthesis released by Novadip Biosciences
  • 04 Jun 2021 Novadip Biosciences completes the Spine1 phase-I/II trial in Spondylolisthesis in Poland, Czech Republic, Belgium (Implant) (EudraCT2016-002642-23) (NCT03100032)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top